Cancer Research

{
  "result": " This tick’s most important advance was a hard-won strategic insight: the swarm had accumulated 181 distinct biological concepts—genes, pathways, and drug targets—yet held zero validated causal relationships among them, a “zero-edge barrier” worsened by off-target literature noise. Rather than continuing to broaden the search, the mission made the critical decision to permanently archive unrelated signals—including cardiac, orthopedic, neural, and other cancer concepts such as Teneurin-4 and triple-negative breast cancer—and narrow its aperture onto two mandated targets, *LDLR* and *PTGS2*, specifically within microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal cancer. By pivoting to a hardened, tissue-specific validation pipeline, the swarm refined six hypotheses and reset its trajectory toward falsifiable causal inference instead of encyclopedic accumulation.\n\nColorectal cancer is not a single disease. MSS tumors, which comprise the majority, differ markedly from MSI tumors in immune infiltration, metabolic wiring, and therapeutic response. The low-density lipoprotein receptor (*LDLR*) governs cholesterol clearance, primarily in the liver but also in the colon, potentially shaping the lipid microenvironment that tumors exploit. *PTGS2*, also known as COX-2, is an inflammation-driving enzyme active in stromal fibroblasts, macrophages, and epithelial cells, and has long been implicated in CRC initiation. Observational studies, however, cannot distinguish whether these molecules are causal drivers or mere passengers. To break through, the swarm designed investigations using genetic instruments—naturally occurring DNA variants that alter a gene’s RNA or protein output in a specific tissue—as unbiased proxies to test causality separately in MSS and MSI contexts.\n\nThe investigation pursued three parallel tracks. First, the swarm mined genetic data from GTEx liver and sigmoid colon to identify variants that regulate *LDLR* expression and protein levels (cis-eQTLs and cis-pQTLs), then prepared colocalization and Mendelian randomization analyses against large multi-ancestry CRC genome-wide association studies stratified by MSS/MSI status, with validation planned in tumor expression and proteomic atlases (TCGA and CPTAC). Second, for *PTGS2*, the swarm extracted cell-type-specific eQTLs from gut and immune single-cell atlases to build stromal-infiltration-stratified instruments, while simultaneously querying DepMap CRISPR knockout screens to test whether shutting down *PTGS2* is synthetically lethal—selectively killing cancer cells that carry *APC* mutations, a hallmark of Wnt-pathway-driven CRC, particularly under MSI conditions. Third, the swarm set up tests for whether metabolic polygenic scores for obesity and dyslipidemia interact with liver-specific *LDLR* variants to modify MSS/MSI risk bidirectionally, including the potential modifying effect of rare regulatory variants in evolutionarily constrained enhancers.\n\nNo new empirical relations were confirmed this tick; the knowledge base remains at 181 entities and zero validated edges. This honest null reflects the genuine difficulty of establishing tissue-resolved, subtype-specific causality, not a failure of concept. The six refined hypotheses now await execution of the exact computational pipelines described above. *LDLR* and *PTGS2* remain promising but unproven nodes in the CRC network: their causal relevance to MSS or MSI biology is suggested by prior literature, yet the swarm’s genetic instruments have not demonstrated colocalization, interaction, or synthetic lethality.\n\nThe immediate horizon is execution. Can the swarm demonstrate that liver- or colon-specific *LDLR* expression signals colocalize with MSS risk alleles at the 19p13.2 locus? Will *PTGS2* single-cell instruments reveal immune-stromal effects invisible to bulk-tissue analysis? And will CRISPR data validate *PTGS2* as a dependency in *APC*-mutant, MSI-conditioned lines but not in *APC*-wild-type counterparts? Answering these questions requires crossing from hypothesis architecture into hardened statistical and experimental validation. The direction is sound, but confidence remains moderate until the first edges are finally forged.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 6
}